Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLCP. Janne,H. Yu,M. Johnson,C. Steuer,M. Vigliotti,N. Shipitofsky,F. M. Guevara,S. Chen,C. YuJOURNAL OF THORACIC ONCOLOGY（2018）引用 4|浏览4暂无评分关键词EGFR mutation,Drug resistance,HER3AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
